Releases
16. May, 2022
Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate
Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing...
Releases
19. April, 2022
First quarter report Q1-2022
Cessatech A/S today releases its results for the period 1 January – 31 March...
Media
5. April, 2022
Altinget: mindre u-hyg-ge-ligt…
“Hospitalophold- og behandling kan være en hård omgang for børn. Med den smertestillende...
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Releases
8. March, 2022
Successful outcome from trial 0204
Cessatech reports successful outcome of bioavailability trial 0204 Topline results of clinical trial 0204...
Releases
3. March, 2022
Annual report 2021 published
Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Releases
6. January, 2022
Changes to the Board of Directors – welcome to Rachel
Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...
Releases
22. December, 2021
Cessatech successfully raises DKK 24.3 million through warrant exercise
During the period 25 November – 16 December 2021, holders of TO 1 have...
Releases
25. November, 2021
Exercise warrants of series TO1 before 14 Dec
In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and...
Releases
2. November, 2021
First US patent covering CT001
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799...
Media
23. September, 2021
#FEMSNABBA…
https://borsvarlden.com/artiklar/Fem-fr%C3%A5gor-till-Jes-Trygved?fbclid=IwAR0sa-omHrXpxrvnQd87xFDRDWZzVQQsIEr6VH9aY7S8BkLbXNzhL6AnShI